Drug Trial Radar · NCT05311085
Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion)
Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
807
Actual
Start
May 5, 2022
Primary completion
May 2, 2024
Study completion Jul 26, 2024
Sponsor
- Lead sponsor
- University of Auckland, New ZealandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research focuses on maximizing the benefits of proven smoking cessation interventions to support people who smoke to quit, as part of the strategy to help New Zealand become smoke-free. A large, pragmatic community-based clinical trial is planned which draws on 15 years of smoking cessation research undertaken by the study team. This research has shown that both cytisine and nicotine e-cigarettes are more effective than nicotine replacement therapy at helping people to quit smoking, and are more acceptable to users. New Zealand research has also shown that text-messages offering advice and support around quitting smoking are highly effective and acceptable. The planned trial will test whether using cytisine and nicotine e-cigarettes together will help more New Zealanders to quit smoking long-term, compared to using cytisine alone or nicotine e-cigarettes alone. Participants in all three groups will also receive smoking cessation text-messaging behavioral support.
Conditions
- Smoking Cessation
Interventions
CytisineDrug
Standard dosing of: * days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day) * days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five. * days 13-16: one tablet every three hours (four tablets/day) * days 17-20: one tablet every 4-5 hours (three tablets/day) * days 21-25: one tablet every six hours (two tablets/day) Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)
Nicotine delivered via an e-cigaretteDrug
Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Cytisine plus nicotine delivered via an e-cigaretteCombination product
Cytisine: Standard dosing of: * days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day) * days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five. * days 13-16: one tablet every three hours (four tablets/day) * days 17-20: one tablet every 4-5 hours (three tablets/day) * days 21-25: one tablet every six hours (two tablets/day) Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day) Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with verified continuous smoking abstinenceTime frame: Six months post-quit date
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute for Health Innovation, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.